Daewoong Pharmaceutical’s Nabota Hits 1 Trillion Won in Cumulative Sales 12 Years Post-Launch
Daewoong Pharmaceutical announced on the 13th that its flagship botulinum toxin product, Nabota, surpassed 1 trillion won in cumulative sales as of...
Search results for "drug treatment"
Maximizing Weight Loss vs. Protecting the Heart: The Paradox of Modern Anti-Obesity Drugs
As global demand for anti-obesity medications surges, a fierce pharmaceutical race is underway to develop next-generation successors to blockbusters...
Daewoong’s Enblo Demonstrates Strong Potential to Reverse Fatty Liver in Diabetes Patients
Daewoong Pharmaceutical announced that its newly developed type 2 diabetes medication, Enblo (active ingredient:...
AI Cancer Gene Analysis and 810 Billion-Won Tech Export Lead South Korea's Top 30 Health Care R&D Achievements
The Ministry of Health and Welfare and the Korea Health Industry Development Institute announced on the 8th that they...
Why Eating Around the Mold on Your Food Is a Dangerous Gamble
“Ugh, what a waste. It’s just a tiny bit, so I should probably just eat it.”When I was young, my grandmother would...
Misdiagnosing Low Testosterone: Why Fatigue and Low Libido May Signal Other Serious Medical Conditions
An increasing number of men are turning to male hormone supplements, but medical experts caution against assuming that...
United Therapeutics Acquires Thymmune, Betting 460 Billion Won on Thymus Cell Therapy
The race to develop regenerative cell therapies for an ultra-rare disease that leaves patients born without a...
Considering Wegovy for Weight Loss? South Korea's Drug Safety Ministry Warns It Is Not for Everyone
South Korea’s Ministry of Food and Drug Safety issued a strong warning on July 8 against the misuse and abuse of GLP-1...
MediPost Begins Pivotal U.S. Phase 3 Trial for Regenerative Knee Therapy Cartistem
South Korean biotechnology company MediPost has entered full-scale Phase 3 clinical testing in the United States for...
Novartis to Buy UK Biotech Myricx for Up to $1.5 Billion, Boosting ADC Portfolio
Novartis is significantly expanding its oncology portfolio after securing an antibody-drug conjugate technology...